State of Wisconsin Investment Board

The State of Wisconsin Investment Board (SWIB) is a state agency tasked with managing investments for the Wisconsin Retirement System (WRS) and several other state trust funds, including the State Investment Fund and various compensation and insurance funds. Established in 1951 and based in Madison, Wisconsin, SWIB invests in public equities, fixed income, real estate, private equity, and alternative markets, primarily focusing on the United States. The organization maintains a diversified investment portfolio, which includes value stocks and various asset classes, employing a fundamental research approach and tactical asset allocation. Investment decisions are made by a professional staff and external managers, adhering to fiduciary responsibilities to ensure benefits for members of the WRS. The firm's trustees oversee overall policies, while individual investment selections are guided by thorough research and risk assessment.

Charles R. Carpenter

Managing Director, Private Markets

John Culley

Associate Portfolio Manager

Anne-Marie Fink

Managing Director, Private Markets

Rochelle Klaskin

Deputy Executive Director/Chief Administrative Officer

Villa CFA, CPA, David C.

Chief Investment Officer

25 past transactions

HistoSonics

Series C in 2020
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

FluGen

Series A in 2017
FluGen, Inc. is a biopharmaceutical company focused on developing vaccines to prevent diseases caused by influenza viruses. Founded in 2007 and based in Madison, Wisconsin, FluGen offers RedeeFlu, a nasal spray vaccine designed to protect against influenza, along with a vaccine-loaded intradermal microneedle delivery device. The company aims to address both seasonal and pandemic influenza on a global scale.

FluGen

Venture Round in 2016
FluGen, Inc. is a biopharmaceutical company focused on developing vaccines to prevent diseases caused by influenza viruses. Founded in 2007 and based in Madison, Wisconsin, FluGen offers RedeeFlu, a nasal spray vaccine designed to protect against influenza, along with a vaccine-loaded intradermal microneedle delivery device. The company aims to address both seasonal and pandemic influenza on a global scale.

EatStreet

Series C in 2015
EatStreet is an online and mobile food ordering service that streamlines commerce between restaurants and diners. To college students and young professionals, EatStreet is a smart, simple, and affordable way to order delivery and takeout from their favorite restaurants. To restaurant owners, EatStreet is a one-stop-shop for online ordering and marketing. By providing web, mobile, and social products for online ordering, EatStreet brings in new business for restaurants. Diners enjoy the upside of fast, simple ordering while restaurants see their sales soar. Founded in 2010, the company is headquartered in Madison, Wisconsin, United States.

FluGen

Series A in 2015
FluGen, Inc. is a biopharmaceutical company focused on developing vaccines to prevent diseases caused by influenza viruses. Founded in 2007 and based in Madison, Wisconsin, FluGen offers RedeeFlu, a nasal spray vaccine designed to protect against influenza, along with a vaccine-loaded intradermal microneedle delivery device. The company aims to address both seasonal and pandemic influenza on a global scale.

NeuWave Medical

Series C in 2015
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.

Rentable

Venture Round in 2015
Rentable is an internet company that specializes in providing a web-based platform that allows its users to conduct an online internet apartment search. The company was established in 2011 and is based in Madison, Wisconsin.

Madison Vaccines

Series A in 2015
Madison Vaccines, Inc., a biopharmaceutical company, develops therapeutic plasmid DNA vaccines. It focuses on bone metastases and prostate cancer. The company is based in United States.

Zurex Pharma

Series B in 2014
Zurex Pharmacy is a specialty pharmacy and medical technology company with a novel antimicrobial technology platform. Their company's mission is to develop and commercialize a portfolio of new antimicrobial products designed to prevent healthcare-acquired infections with a focus on surgical site wounds and catheter-related infections. It was founded in 2010 and is headquartered in Middleton, Wisconsin.

Datica

Venture Round in 2014
Datica is a cloud-based healthcare platform established in 2013 and headquartered in Minneapolis, Minnesota. The company specializes in facilitating clinical data exchange for highly regulated industries, particularly in healthcare. Datica's platform enables developers to implement cloud-based user management, secure messaging, and data storage without the complexities of server configuration. This functionality supports the integration of electronic health records (EHR) and ensures compliance with industry regulations. Datica serves a diverse clientele, ranging from mid-to-late-stage startups to Fortune 100 companies, helping them manage sensitive information effectively while streamlining their operations and enhancing data interoperability.

Neurovance

Series A in 2014
Neurovance, Inc., a neuroscience-focused company, focuses on the development and commercialization of therapies for adult and children with attention deficit hyperactivity disorders. The company develops centanafadine, a triple reuptake inhibitor that modulates the activity of norepinephrine dopamine and serotonin in a specific ratio. Neurovance, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. As of March 31, 2017, Neurovance, Inc. operates as a subsidiary of Otsuka America, Inc..

EatStreet

Series B in 2014
EatStreet is an online and mobile food ordering service that streamlines commerce between restaurants and diners. To college students and young professionals, EatStreet is a smart, simple, and affordable way to order delivery and takeout from their favorite restaurants. To restaurant owners, EatStreet is a one-stop-shop for online ordering and marketing. By providing web, mobile, and social products for online ordering, EatStreet brings in new business for restaurants. Diners enjoy the upside of fast, simple ordering while restaurants see their sales soar. Founded in 2010, the company is headquartered in Madison, Wisconsin, United States.

Madison Vaccines

Series A in 2014
Madison Vaccines, Inc., a biopharmaceutical company, develops therapeutic plasmid DNA vaccines. It focuses on bone metastases and prostate cancer. The company is based in United States.

Datica

Series A in 2013
Datica is a cloud-based healthcare platform established in 2013 and headquartered in Minneapolis, Minnesota. The company specializes in facilitating clinical data exchange for highly regulated industries, particularly in healthcare. Datica's platform enables developers to implement cloud-based user management, secure messaging, and data storage without the complexities of server configuration. This functionality supports the integration of electronic health records (EHR) and ensures compliance with industry regulations. Datica serves a diverse clientele, ranging from mid-to-late-stage startups to Fortune 100 companies, helping them manage sensitive information effectively while streamlining their operations and enhancing data interoperability.

Montage

Series B in 2012
Montage Talent, Inc. specializes in providing live and on-demand voice and video interviewing solutions tailored for large enterprises, healthcare sectors, and staffing and recruitment process outsourcing firms. Established in 2007 and based in Delafield, Wisconsin, the company was previously known as Expressume, Inc. and adopted its current name in 2001. Montage serves a diverse clientele, including numerous Fortune 500 companies, by delivering a modern hiring experience that combines advanced technology with personalized service. As a pioneer in purpose-built video interviewing, Montage's proprietary platform is designed for reliability, scalability, compliance, and security, ensuring it meets enterprise demands. The company emphasizes innovation driven by market needs and data, aiming to enhance the efficiency and predictability of talent acquisition. Additionally, Montage is dedicated to fostering long-term client relationships and providing exceptional support at every stage of the hiring process.

Neurovance

Venture Round in 2012
Neurovance, Inc., a neuroscience-focused company, focuses on the development and commercialization of therapies for adult and children with attention deficit hyperactivity disorders. The company develops centanafadine, a triple reuptake inhibitor that modulates the activity of norepinephrine dopamine and serotonin in a specific ratio. Neurovance, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. As of March 31, 2017, Neurovance, Inc. operates as a subsidiary of Otsuka America, Inc..

NeuWave Medical

Series B in 2012
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.

Mithridion

Series B in 2009
Mithridion is a biopharmaceutical company that discovers and develops drugs for central nervous system disorders, with an initial focus on Alzheimer's disease and schizophrenia.

Pinstripe

Series A in 2005
Pinstripe is a top RPO provider with global reach and high customer satisfaction as recognized by HRO Today’s Baker’s Dozen. They serve world-class organizations in financial services, healthcare, pharmaceuticals, technology, advanced manufacturing, biotech, telecommunications and energy.

OpGen

Series B in 2005
OpGen, Inc. is a precision medicine company based in Gaithersburg, Maryland, focused on developing molecular diagnostics and informatics to address infectious diseases. The company produces various products, including the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and genetic markers of antimicrobial resistance in urine and other samples, and QuickFISH and PNA FISH tests for identifying pathogens in blood cultures. OpGen also offers the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient data to provide insights for managing multidrug-resistant organisms in healthcare settings. The company collaborates with the New York State Department of Health to enhance detection and management of antimicrobial-resistant infections in healthcare institutions. Additionally, OpGen is advancing DNA analysis and genomics through its Argus Whole Genome Mapping System and MapIt Services, catering to academic and research sectors worldwide. Founded in 2001, OpGen aims to improve patient outcomes and reduce the spread of infections caused by resistant microorganisms.

Zystor

Series A in 2004
ZyStor Therapeutics, Inc. is a privately-held biotechnology company developing enzyme replacement therapies for the treatment of lysosomal storage diseases.

Roche NimbleGen

Series D in 2003
Roche NimbleGen provides products and services to the life science research market. The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow and order different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents. The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services. Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG.

Roche NimbleGen

Series B in 2001
Roche NimbleGen provides products and services to the life science research market. The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow and order different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents. The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services. Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG.

Cardiac Pathways Corp

Venture Round in 2000
Cardiac Pathways Corp manufactures minimally-invasive systems used by electrophysiologists to diagnose and treat cardiac tachyarrhythmia (abnormally rapid heart rhythms), which if untreated can cause palpitations, fainting, and sudden cardiac arrest. Cardiac Pathways' products consist principally of systems for performing ablation treatment (a nonsurgical, minimally-invasive technique for neutralizing heart tissue responsible for starting or maintaining a tachyarrhythmia) and for diagnostic mapping (locating the source of the tachyarrhythmia within the heart). Cardiac Pathways was issued a U.S. patent related to its Real-time Position Management Tracking System. Founded in 1991, Cardiac Pathways is based in Sunnyvale, California. As of August 6, 2001, it was acquired by Boston Scientific Corporation.